{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"25.9","value":"0"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"58.2","value":"16.7"},{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"31.6","value":"7.7"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"75.1","value":"25.0"},{"groupId":"OG004","lowerLimit":"16.3","upperLimit":"48.7","value":"30.8"},{"groupId":"OG005","lowerLimit":"0.6","upperLimit":"42.9","value":"11.1"},{"groupId":"OG006","lowerLimit":"7.1","upperLimit":"40.1","value":"20.0"},{"groupId":"OG007","lowerLimit":"15.3","upperLimit":"61.0","value":"35.7"},{"groupId":"OG008","lowerLimit":"0.3","upperLimit":"22.6","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"19"}],"units":"Participants"}],"description":"Percentage of participants who achieved an objective response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumor (RECIST) v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to \\<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose expansion in TNBC. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG000","title":"Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG001","title":"Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG002","title":"Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG003","title":"Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG004","title":"Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG005","title":"Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG006","title":"Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG007","title":"Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG008","title":"Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Part 2 mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline to PD or Death due to Any Cause (Up to 1.54 years)","title":"Objective Response Rate (ORR) (Part 2 Expansion)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}